SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Maclean, D.
Right arrow Articles by Sandilands Readman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Maclean, D.
Right arrow Articles by Sandilands Readman, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Felodipine Compared to Nifedipine as "Third-Line Drug" in Resistant Hypertension

Derek Maclean

From the Department of Pharmacology and Clinical Pharmacology, University of Dundee, Dundee, Scotland

Elizabeth Thomson Mitchell

From the Department of Pharmacology and Clinical Pharmacology, University of Dundee, Dundee, Scotland

Ann Sandilands Readman

From the Astra Clinical Research Unit, Edinburgh, Scotland

Felodipine is a new dihydropyridine calcium antagonist, and in hypertension it is a much more effective "third-line" drug than hydralazine. Nifedipine, on the other hand, is the established dihydropyridine calcium antagonist that has been increasingly used to treat hypertension. Information is now needed on the relative merits and demerits of these two drugs. This study appraised, there fore, the therapeutic utility of twelve months' treatment with nifedipine 20-60 mg twice daily in 55 patients with previous drug-resistant hypertension who had been successfully treated for the previous year with felodipine 5-20 mg twice daily, each calcium antagonist being used in combination with atenolol 100 mg daily with or without chlorthalidone 25 mg daily. Initially, nifedipine main tained comparable blood pressure control to that which had been achieved by felodipine, although in the longer term (over eight months) nifedipine proved less effective than felodipine had (p < 0.02) and more patients became uncon trolled (supine diastolic blood pressure, Phase V, ≥90 mmHg) on the maximum tolerated dose of the calcium antagonist ({chi}2=4.13, p < 0.05 > 0.025). The former degree of blood pressure control was, however, reestablished by increas ing the dose of nifedipine or reintroducing the diuretic as necessary, and this control was maintained over the next four months.

Minor side efects were less common on nifedipine than they had been during the preceding felodipine treatment phase.

Felodipine thus has more pronounced and sustained antihypertensive effects than nifedipine, though its side effect burden may appear to be greater. Because of possible treatment order effects and the development of tolerance to dihydro pyridine side effects, formal comparison of these two compounds is warranted.

Angiology, Vol. 37, No. 11, 840-845 (1986)
DOI: 10.1177/000331978603701108


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement